Global CD233 Antibody Market Clinical Trials Intelligence 2028

Global CD233 Inhibitors Trials Intelligence Report Highlights:

• Global CD233 Inhibitors Market Dynamics
• Clinical Approaches to Target CD233 Inhibitors
• Role of CD233 Inhibitors in Cancer, Autoimmune Disorders
• Number of CD233 Inhibitors Drug In Trials
• CD233 Inhibitors Approved Patent Insight
• CD233 Inhibitors Trials By Phase, Company, Country, Indication
• Company Agreement/Partnership/Deals For Ongoing Trials
• Global CD233 Inhibitor Market Future Outlook

For Report Sample Contact neeraj@kuickresearch.com

The successful application of the anti-CTLA-4 and anti-PD-1/PD-L1 mAbs has paved the way to a new era of anticancer therapy changing the therapeutic scenario in a number of tumor settings. However, clinical benefit is still limited to a subset of patients, which is likely due to the heterogeneity of the cancer immunogenic profile during growth and dissemination, and acquisition of resistance mechanisms. Further, co-administration of PD-1/PD-L1 and CTLA-4 inhibitor has strengthened the evidence that the combination of drugs targeting different immune checkpoint regulatory pathways is a feasible approach to improve treatment efficacy and potentially delay or prevent tumor resistance.

The better understanding about tumor microenvironment and has led to identification of several co-stimulatory receptors including CD223, TIM-3, and TIGIT, which display functional redundancy with CTLA-4 and PD-1/PD-L1 axes. Among all, CD223 or lymphocyte activation gene-3 has gained considerable interest among research institutions and pharmaceutical sectors. CD223 is an immune checkpoint receptor protein found on the cell surface of effector T cells and regulatory T cells (Tregs) and functions to control T cell response, activation, and growth. In addition to this, these molecules are also expressed in tumor microenvironment which makes them potential target in cancer immunotherapy.

The identification of novel immunoreceptor has surged the development of novel CD223 targeting drugs in preclinical and clinical development. Several potential inhibitors including Relatlimab, IMP321, LAG525, MGD013, MK4280, FS118, and other are present in early phase of clinical development and will transform the cancer immunotherapy in 4-5 years. Recently in 2021, Relatlimab has received priority review from US FDA and it is expected to enter the market by 2022. The entrance of these drugs in the market by next year is expected to transform the overall cancer therapeutics market. It is expected that the market will be inclined more towards immunotherapy in coming years which is mainly due to their ability to overcome PD-1/PD-L1 drug resistance in cancer patients.

Beyond the inhibitory activity of CD223 on different types of cancers, CD223 may also be necessary to negatively regulate autoimmunity in many disease-prone environments. For instance, loss of LAG-3 substantially can accelerate type 1 diabetes in Non-Obese Diabetic (NOD) mice with 100% incidence. LAG-3 deficient mice can exhibit increased antigen-reactive CD4+ and CD8+ T cells infiltration in the islets, accompanied by invasive and rapid insulitis. Therefore, researchers are also expanding their knowledge of targeting CD223 signaling pathways as an alternative approach to manage other therapeutic indications, which is further boosting the market growth.

The global CD223 targeted therapeutics is expected to surpass US$ XX Billion by 2028. The growing burden of critical diseases such as cancer, leukemia, lymphoma, and muscular degeneration are the major factors that boost the adoption of CD223 targeting drugs among the global population. The growing adoption of technological advancements in the field of biopharmaceutical and rising consumer awareness regarding the safety of the CD223 targeted therapeutics will also be fueling the market growth during the forecast period. In addition, the increased efficiency of the novel CD223 targeted drugs to treat such deadly diseases with minimal side effects is also major driving factor of the market.

US is expected to be the leading consumer of the CD223 targeted therapeutics owing to the increased adoption rate and higher demand for the advanced and innovative products. The rapidly booming biologics industry is a significant factor that propels the growth of the targeted therapeutics market in US. Further, the presence of numerous CMOs and CROs along with the various biopharmaceutical companies together contributes towards the market development. Moreover, the rising geriatric population, increased disposable income, presence of high-end technologies and developed healthcare infrastructure, and rising demand for the biologic drugs is fueling the growth of the targeted therapeutics in US.

Contact:

Neeraj Chawla
Research Head
Kuick Research
neeraj@kuickresearch.com
+919810410366

Delhi
India

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

This release was published on openPR.